Dr. Patnaik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4383 Medical Dr
San Antonio, TX 78229Phone+1 210-593-5700Fax+1 210-593-5992
Education & Training
University of Toronto Faculty of MedicineClass of 1992
Certifications & Licensure
TX State Medical License 2000 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) Start of enrollment: 2007 May 01
- Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 91 citationsA phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.Renata Ferrarotto, Gail Eckhardt, Amita Patnaik, Patricia LoRusso, Leonardo Faoro
Annals of Oncology. 2018-07-01 - 6 citationsFirst-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea Bullock, Randolph S Watnick
Communications Medicine. 2024-01-13 - 333 citationsFirst-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, Sumit A. Shah, Sreenivasa R Chandana
Journal of Clinical Oncology. 2016-05-20
Press Mentions
selfBACK App Developed by Norwegian University of Science Can Help Relieve Back PainAugust 3rd, 2021- START Launches New Phase I Clinical Trial Program in UtahJune 8th, 2021
- Nektar Therapeutics Announces Its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)May 18th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
